Two Sigma Investments LP Purchases 211,421 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Two Sigma Investments LP boosted its stake in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 79.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 476,291 shares of the company's stock after acquiring an additional 211,421 shares during the period. Two Sigma Investments LP owned 0.67% of Ventyx Biosciences worth $1,043,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. AXQ Capital LP bought a new position in shares of Ventyx Biosciences during the 4th quarter valued at about $29,000. Palumbo Wealth Management LLC increased its stake in Ventyx Biosciences by 97.1% in the 4th quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company's stock worth $52,000 after acquiring an additional 11,792 shares during the last quarter. MetLife Investment Management LLC raised its holdings in shares of Ventyx Biosciences by 76.0% during the 4th quarter. MetLife Investment Management LLC now owns 26,731 shares of the company's stock worth $59,000 after acquiring an additional 11,543 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Ventyx Biosciences by 23.3% during the 4th quarter. Wells Fargo & Company MN now owns 41,170 shares of the company's stock valued at $90,000 after acquiring an additional 7,768 shares during the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Ventyx Biosciences by 12.4% in the fourth quarter. American Century Companies Inc. now owns 67,329 shares of the company's stock valued at $147,000 after purchasing an additional 7,414 shares in the last quarter. 97.88% of the stock is owned by hedge funds and other institutional investors.

Ventyx Biosciences Stock Up 4.1%

Ventyx Biosciences stock traded up $0.10 during mid-day trading on Monday, reaching $2.56. 1,742,987 shares of the company's stock traded hands, compared to its average volume of 1,352,324. Ventyx Biosciences, Inc. has a 12-month low of $0.78 and a 12-month high of $3.51. The stock has a 50 day moving average of $1.35 and a two-hundred day moving average of $1.73. The company has a market cap of $182.17 million, a price-to-earnings ratio of -1.08 and a beta of 0.85.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.09. As a group, sell-side analysts forecast that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current year.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.